RT Journal
A1 Rapoport AM, Tepper SJ
T1 TRiptans are all different
JF Archives of Neurology
JO Archives of Neurology
YR 2001
FD September 1
VO 58
IS 9
SP 1479
OP 1480
DO 10.1001/archneur.58.9.1479
UL http://dx.doi.org/10.1001/archneur.58.9.1479
AB 
THERE ARE 4 triptans currently available in the United States, and 3 more are expected to be approved by the Food and Drug Administration. Although they are all 5-HT1B/1D(serotonin1B/1D) agonists, they each have slightly different pharmacokinetic characteristics and clinical strengths and weaknesses, and they can be used in special ways to optimize migraine therapy. Thus, triptans differ significantly clinically, and the astute clinician uses these differences to optimize patient treatment.1- 2